|1.||Gross, G J: 1 article (07/2000)|
|2.||Moore, J: 1 article (07/2000)|
|3.||Sowell, C G: 1 article (07/2000)|
|4.||Weber, P A: 1 article (07/2000)|
|5.||Walker, E B: 1 article (07/2000)|
|6.||Elliott, G T: 1 article (07/2000)|
07/01/2000 - "Intravenous pretreatment with RC-552 (35 microg/kg) either 24 h or 10 min prior to five 5 min repetitive cycles of ischemia and reperfusion significantly improved regional myocardial segment shortening (percentage of control) at all time points during 2 h of reperfusion in dogs. "
07/01/2000 - "These effects of RC-552 in either cardiac injury model occurred independent of differences in AAR, transmural blood flow during ischemia or hemodynamics throughout the experiment. "
12/01/1999 - "Acute buffer perfusion with RC-552 (0.1, 1.0, or 2.5 microg/ml) for 8 min immediately before ischemia-reperfusion did not reduce infarct size significantly. "
12/01/1999 - "Adult mice were pretreated with vehicle or RC-552 (350 microg/kg ip, n = 7 mice/group) 24 h before global ischemia and reperfusion in a Langendorff isolated, perfused heart model. "
07/01/2000 - "Administration of the non-specific inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine (30 mg/kg, subcutaneously) 1 h prior to ischemia blocked the ability of RC-552 (35 microg/kg, 24 h pretreatment) to reduce infarct size. "
12/01/1999 - "Myocardial infarct size was significantly reduced from 19.2 +/- 2.0% in vehicle to 8.2 +/- 2.9% in RC-552 group (P < 0.05). "
07/01/2000 - "Likewise, RC-552 did not induce secretion of the proinflammatory cytokines TNF, IL-6 or IL-8 from THP-1 cells or alter the expression of adhesion molecules on human neutrophils at concentrations up to 10 microg/ml. MLA was active in these systems at concentrations in the range 0.1-1.0 microg/ml. In conclusion, RC-552 reduces myocardial infarct size and stunning in dogs in the absence of residual immunomodulatory activity."
|3.||Myocardial Stunning (Stunned Myocardium)
|4.||Myocardial Ischemia (Ischemic Heart Diseases)
07/01/2000 - "RC-552 administered to dogs as a bolus intravenous dose (35-70 microg/kg) either 24 h or 10 min prior to 60 min of regional myocardial ischemia and 3 h of reperfusion significantly (P<0.05 v control) reduced infarct size (IS) as assessed by triphenyltetrazolium staining from 27.0+/-2.3% of the area-at-risk (AAR) to 13.3+/-2.2% and 15.0+/-3.0%, respectively. "
|1.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|2.||Interleukin-8 (Interleukin 8)
|4.||Interleukin-6 (Interleukin 6)
|5.||monophosphoryl lipid A